

Investor Presentation

Aug 2011

inspiring
synergies

Disclaimer



This presentation and the accompanying slides (the "Presentation"), which has been prepared by Strides Arcolab Limited (the "Company"), has been prepared for information purposes only and is not, and is not intended to be, an offer, or solicitation of offer, or invitation or recommendation to buy or sell any securities of the Company, and shall not constitute an offer, solicitation or invitation or recommendation to buy or sell in any jurisdiction in which such offer, solicitation or invitation or recommendation is unlawful. No part, or all, of this Presentation shall form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities of the Company.

Nothing in the foregoing shall constitute and/or deem to constitute an offer or an invitation to an offer, to be made to the Indian public or any section thereof through this document, and this document and its contents should not be construed to be a prospectus in India. This document has not been and will not be reviewed or approved by any statutory or regulatory authority in India or by any stock exchange in India.

This Presentation is strictly confidential and may not be copied, published, distributed or transmitted to any person, in whole or in part, by any medium or in any form for any purpose. The information in this Presentation is being provided by the Company and is subject to change without notice. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This Presentation contains statements about future events and expectations that are forward-looking statements. These statements typically contain words such as "expects" and "anticipates" and words of similar import. Any statement in this Presentation that is not a statement of historical fact is a forward-looking statement that involves known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. None of the future projections, expectations, estimates or prospects in this Presentation should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in the Presentation. The Company assumes no obligations to update the forward-looking statements contained herein to reflect actual results, changes in assumptions or changes in factors affecting these statements.

You acknowledge that you will be solely responsible for your own assessment of the market, the market position, the business and financial condition of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.

This Presentation speaks as of 30th May 2011. Neither the delivery of this Presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since that date.

This Presentation is not being made and will not be made directly or indirectly in or into, or by use of the mails of, or by any means or instrumentality of interstate or foreign commerce of, or any facilities of a national securities exchange of, the United States. This includes, but is not limited to, facsimile transmission, electronic mail, telex, telephone and the Internet. Neither this Presentation nor any copy of this Presentation is being, and must not be taken or transmitted into the United States or distributed, directly or indirectly, in the United States. The information presented herein is not an offer for sale within the United States of any equity shares or other securities of the Company. No offering of the Company's securities is being made nor will any offering of the Company's securities be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"). Accordingly, unless an exemption from registration under the Securities Act is available, the Company's securities may not be offered, sold, resold, delivered or distributed, directly or indirectly, into the United States.

This Presentation is confidential and is only addressed to and directed at persons who are "qualified investors" within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC) and (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and Article 49(2)(a) to (d) of the Order, and (ii) to whom it may otherwise lawfully be communicated (all such persons together being referred to as "Relevant Persons"). This Presentation must not be acted on or relied upon in the United Kingdom, by persons who are not Relevant Persons. Any investment or investment activity to which this Presentation relates is available only to Relevant Persons.

The distribution of this Presentation in certain jurisdictions may be restricted by law and persons into whose possession this Presentation comes should inform themselves about and observe any such restrictions

Local market value ("LMV") is provided as a reference for assessing the overall market value for a particular type of pharmaceutical product. It should not be considered as an indicator of Strides' sales of any its pharmaceutical products or the expected performance of such products in the future. Extrapolation of performance for a particular product from LMVs for such types of products, is an inappropriate use of LMV data. There can be no assurance that our approved pharmaceutical products will be successfully commercialized, or that our current filings will be approved

An abstract graphic consisting of numerous thin, curved lines that flow from the left side of the frame towards the right. The lines are color-coded in a gradient, starting with light blue on the left, transitioning through green, and ending in yellow on the right. The lines are densely packed and overlap, creating a sense of movement and depth. The overall shape is reminiscent of a stylized 'Y' or a branching path.

Introduction


Company overview



Overview

- A leading Indian Pharmaceutical company operating in two major segments: Specialties and Pharma
- Offers wide range of products covering Orals, Semi Solids and Specialty injectables including Beta-lactams, Cephalosporins, Oncolytics and Penems
- Has one of the largest Lyophilization (freeze drying) capacities in the world
- Amongst the leading manufacturers of Soft Gelatin capsules in the world
- Partnerships with leading global players like Pfizer, GlaxoSmithKline, Aspen, Novartis, Sandoz, and Teva

Revenue growth (US\$mn)




Geographical presence: 14 manufacturing plants + marketing operations in 75 countries


Marketing presence

Plant locations

1. Campos, Brazil
2. Lagos, Nigeria
3. Bangalore & Mumbai, India
4. Milan, Italy
5. Warsaw, Poland
6. Jurong, Singapore



Filings & approvals track record (ANDA)



2009	Revenue by geography ⁽¹⁾	2010	% Split	% Growth
US\$mn		US\$mn		
	Established Markets			
62	Australia	97	26%	56%
29	North America	86	23%	200%
30	Europe	41	11%	37%
8	South Africa	8	2%	-1%
129	Sub-Total	232	62%	80%
157	Emerging Markets	139	38%	-11%

Note: USD/INR exchange rate used: 45.67

Amongst highest steriles approvals in the industry in 2010

* Actual YTD




4 Note: (1) Does not include 'other income' of US\$ 5 mn and US\$ 15mn respectively

Strides Arcolab – Business Overview



	PHARMA & BRANDED GENERICS BUSINESS (NON STERILES)	SPECIALTIES BUSINESS (STERILES)
FINANCIAL OVERVIEW	CY2009 Revenue: US\$ 209 mn EBITDA: US\$ 26 mn (12.4% margin) CY 2010 Revenue: US\$ 236 mn EBITDA: US\$ 38 mn (16.1% margin)	CY2009 Revenue: US\$ 82 mn EBITDA: US\$ 20 mn (24.5% margin) CY 2010 Revenue: US\$ 151 mn EBITDA: US\$ 49 mn (32% margin)
BUSINESS	<ul style="list-style-type: none"> Manufacturing & Branded Generics (Orals) 	<ul style="list-style-type: none"> Sterile Injectable Generics and Specialties
KEY MFG. LOCATIONS	<ul style="list-style-type: none"> 6 Global Manufacturing Plants - 3 in India and one each in Milan(Italy), Singapore and Nigeria 	<ul style="list-style-type: none"> 8 Global Manufacturing Plants - 5 in India, 2 in Brazil and 1 in Poland
KEY PRODUCTS	<ul style="list-style-type: none"> Tablets, Soft Gel Capsules, Hard Gel Capsules, Sachets, Capsules, Liquids / Syrups and Creams 	<ul style="list-style-type: none"> Sterile injectable across a wide range of therapeutic areas Lyophilized vials, Liquid vials, Dry powder vials, Pre filled syringes, Ampoules and Devices
KEY TARGET MARKETS	<ul style="list-style-type: none"> Branded generics markets in India, Africa and Australasia IP led manufacturing business and leading provider for multilateral funding programmes in AIDS, TB and Malaria 	<ul style="list-style-type: none"> US, Europe, Latin America. ANZ etc.
KEY CUSTOMERS	<ul style="list-style-type: none"> Pfizer, Aspen, Sandoz, Apotex, Galen etc Multilateral agencies including UNICEF, PEPFAR, Clinton Foundation etc 	<ul style="list-style-type: none"> Pfizer, GSK, Teva, Actavis, Sagent, Novartis etc



Strides – Key differentiators



1 Integrated capabilities spanning entire product development cycle

- Full services provider from identifying business opportunities to product approval and commercialization

2 Focus on R&D resulting in industry leading formulation expertise

- Proven R&D capabilities for developed markets
- Employs around 350 scientists in its R&D department, delivering average 40 ANDAs annually

3 Targeting products with significant demand

- Increasingly targets products that are (i) in short supply (ii) near term patent expiries (iii) difficult to manufacture segments
- Moving towards larger sized molecules

8 Diversified portfolio across Specialties and Pharma offers stability

- Offers wide range of products covering Orals, Semi Solids and Specialty injectables including Beta-lactams, Cephalosporins, Oncolytics and Penems
- Broad product portfolio is critical for getting GPO contracts in the US (Strides has a contract for sterile injectables with Premier)



4 Solid track record of filings and approvals

- 157 ANDA filings (119 in steriles) and 62 Approvals (40 in steriles) till date
- Branded generics product registrations: 300+ in Africa, 60+ in Australia, and 400+ in eight South East Asian markets

7 Partnership with Big Pharma

- Partnerships with pharmaceutical majors such as Pfizer, GSK, Novartis, Teva & Aspen in US, Europe, Australia, LATAM, and South Africa
- Recent partnerships with Pfizer and GSK validates Strides' niche capabilities in sterile injectables and pharmaceuticals portfolio

6 Solid track record of regulatory compliance

- Successful inspections by USFDA/EMA/PIC over the last few years.
- Continue to maintain strong track record in all Regulatory inspections.

5 Significant investments completed in manufacturing facilities

- Significant investments completed in specialties space
- Recently FDA approved facilities will accelerate the developed markets strategy

agila
Rebranded Specialties Business



The core business going forward.....

Steriles - Snapshot



Key strengths

One of the most competitive steriles franchise globally with 8 manufacturing facilities

One of the largest lyophilization (freeze drying) capacities in the world

Full services player with a well diversified portfolio

Track record of filing average 35 ANDAs annually in the last three years

Significant investment in manufacturing facilities completed

Long term customer contracts and joint ventures to provide stable revenue stream


Product categories – Wide range

- High Potency Drugs (Oncology, Peptides and Controlled Substances)
- Antibiotics
- Penems & Penicillins
- Cephalosporins
- Suspension injections
- Oncology
- **Ophthalmics and Peptides to be new domains**

Packaging formats – All major types

- Vials – Liquid & Dry Powder
- Pre filled syringes (PFS)
- Ampoules
- Market leading ability to package in lyophilized form
- **Focus on pre filled syringes and lyophilized formats**

FDA injectables ANDA approvals by company 2008-2010



Note: * Includes product approvals with JV partners & ANDAs sold to Pfizer in Dec 2010
Source: Approval data sourced from US FDA

Market Opportunity



Key industry trends

- Convergence of branded pharma and generics
 - Increasing investments by innovators in generics
- Injectables is the key growth area
 - Oncology and generic biologics (biosimilars) hold significant potential
 - Injectable oncology segment patents to expire by 2015, current market estimated @ USD 8.3 billion *(Source: IMS)*
 - Regulatory pathways for biosimilars in developed markets being implemented
 - Limited pricing pressure in generic injectables
- Limited injectable manufacturing capacities globally
- Major Injectable Manufacturers currently facing regulatory and compliance challenges with FDA
- Scarcity value in the injectables space leading to consolidation


Year	Acquiror	Target	Deal size
2010	Mylan	Bioniche (USA)	c.US\$ 550mn
2010	Recipharm	Madaus (Germany)	n.a.
2009	Hospira	Orchid (India)	c.US\$ 400mn
2009	Novartis	Ebewe (Austria)	c.US\$ 1.2bn

Source: Deal announcements

Injectable market


- Overall injectable market @ US\$ 200bn for the year 2009

Break up by region (US\$m) - 2009



Source: IMS Health as on 10 Aug 2010

Competition for generic injectables in the US – Few competitors per product



- Majority of specialty injectables are in niche areas and attract little competition
- For more than half of the injectable generics approved since 2004, just 1 or 2 manufacturers have received ANDA approvals and 86% of molecules have fewer than 5 generic competitors
- Only ten drugs have attracted eight or more competitors

Source: ESPICOM report titled "Injectable Generic Drugs: Prospects & Opportunities to 2014"

Drug Shortages in US

178 drug Shortage in US in 2010, majority of products are injectables



Shortages of drugs in US

- ✓ **2010** - 102 (57%) drugs out of list of 178 drugs were steriles
- ✓ **2009** - 73 (46%) drugs out of list of 157 drugs were steriles
- ✓ **2008** - 39 (35%) drugs out of list of 110 drugs were steriles


Why shortages ?

- Process complexity & relatively long manufacturing lead time
- A limited number of companies are able to make sterile injectable products

Strides' preparedness to meet steriles drug shortages in US

- Strides pipeline includes drugs which are part of FDA shortage list
- Strides launched Vancomycin through JV partner and later through Pfizer helped mitigating drug shortage situation

Total number of drug shortages and shortages involving sterile injectables drugs in United States, 2005-2010



Data is from the Drug Shortage Program, Center for Drug Evaluation and Research, FDA and does not include shortages of vaccines, immune globulin products, or other biologic products that are managed by FDA's Center for Biologics Evaluation and Research

Source: The New England Journal of Medicine and Drug Shortage Summit Held in Nov'2010 organized by American Society of Health-System Pharmacists (ASHP)

Strategy focusing on capturing higher value business and sustainable growth



	Phase-I [2005-2007]	Phase-II [2008-2010]	Current Phase [2011-2015]																																								
PRODUCT FILINGS	<table border="1"> <thead> <tr> <th>Segment</th> <th>Nos of Filings</th> <th>LMV \$bn</th> <th>Avg LMV \$mn</th> </tr> </thead> <tbody> <tr> <td>Steriles</td> <td>27</td> <td>0.7</td> <td>26</td> </tr> <tr> <td>Oncology</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Pens & Penems</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Total</td> <td>27</td> <td>0.7</td> <td></td> </tr> </tbody> </table>	Segment	Nos of Filings	LMV \$bn	Avg LMV \$mn	Steriles	27	0.7	26	Oncology	-	-	-	Pens & Penems	-	-	-	Total	27	0.7		<table border="1"> <thead> <tr> <th>Segment</th> <th>Nos of Filings</th> <th>LMV \$bn</th> <th>Avg. LMV \$mn</th> </tr> </thead> <tbody> <tr> <td>Steriles</td> <td>52</td> <td>3.2</td> <td>62</td> </tr> <tr> <td>Oncology</td> <td>31</td> <td>3.9</td> <td>126</td> </tr> <tr> <td>Pens & Penems</td> <td>9</td> <td>0.7</td> <td>78</td> </tr> <tr> <td>Total</td> <td>92</td> <td>7.8</td> <td></td> </tr> </tbody> </table>	Segment	Nos of Filings	LMV \$bn	Avg. LMV \$mn	Steriles	52	3.2	62	Oncology	31	3.9	126	Pens & Penems	9	0.7	78	Total	92	7.8		<p>High value creation domains</p> <ul style="list-style-type: none"> ➤ Biosimilars ➤ Devices and delivery systems ➤ Para IV & 505b(2) ➤ To emerge as a first wave player for most products going off-patent
Segment	Nos of Filings	LMV \$bn	Avg LMV \$mn																																								
Steriles	27	0.7	26																																								
Oncology	-	-	-																																								
Pens & Penems	-	-	-																																								
Total	27	0.7																																									
Segment	Nos of Filings	LMV \$bn	Avg. LMV \$mn																																								
Steriles	52	3.2	62																																								
Oncology	31	3.9	126																																								
Pens & Penems	9	0.7	78																																								
Total	92	7.8																																									
MFG. CAPABILITIES	<ul style="list-style-type: none"> ➤ Building Global manufacturing capabilities for Steriles, Cephalosporin's & Betalactams 	<ul style="list-style-type: none"> ➤ Consolidation and expansion of Global manufacturing capabilities for Steriles Injectables and Oncology 	<ul style="list-style-type: none"> ➤ New Investments for next level of growth: Integrated Biosimilar, Penems & Penicillin facility 																																								
STRATEGY	<ul style="list-style-type: none"> ➤ Focus on Niche small value opportunistic products with distribution of products through JV model 	<ul style="list-style-type: none"> ➤ Focus on large value Niche Sterile and Oncology products ➤ Partnering with Big Pharma's Pfizer, Apotex, Teva etc with profit sharing arrangement 	<ul style="list-style-type: none"> ➤ Strengthening partnership for new products/partners & new Geographies ➤ Building front ending business in select geographies of USA, UK, Canada, Asia, Turkey, Indonesia, India, Nordic and Brazil ➤ Continuing Licensing opportunities in selected domains 																																								

Agila Value Chain synergies for next level growth




Biologics	<ul style="list-style-type: none"> ➤ Expected Market to reach \$225 Bn by 2015 ➤ Acquired 70% controlling stake in Inbiopro-a biotechnology focused company ➤ Immediate access to a pipeline of 8 products (including 5 MAB's), estimated to have global sales of US\$ 28 billion; commercialization expected to begin in 2013 in emerging markets
Front Ending	<ul style="list-style-type: none"> ➤ Building frontend Sales and Marketing capabilities to capture market share in the selected geographies of USA, Canada, Brazil, Nordic, South-East Asia, India, Turkey and Indonesia
Value Generics	<ul style="list-style-type: none"> ➤ Creating portfolio of fewer but valuable products in R&D and to achieve capabilities with first-to-file, Para-IV, delivery systems and devices
Oncology	<ul style="list-style-type: none"> ➤ State-of-art manufacturing facility at Bangalore approved by all key Regulated agencies including USFDA with one of the broadest portfolio of Oncology products in the industry covering all major formats ➤ Global partnership with Big Pharma for established and emerging market
Penems	<ul style="list-style-type: none"> ➤ Top 3 Penems covering 90% of the Global Market in pipeline, 2 ANDA'a already filed awaiting approval ➤ Brazil Penem facility approved by major regulatory agencies like MHRA, ANVISA etc ➤ USFDA inspection in H2'11
Steriles Injectables	<ul style="list-style-type: none"> ➤ Wide portfolio of injectable products including Cephalosporins, Beta-Lactum and Niche Steriles ➤ Marketing tie ups with Big Pharma for key geographies

Well Positioned For Regulated Markets Opportunity



Increasing focus on high value products


NUMBER OF ANDA FILINGS (LMV - \$8 Bn)



Oncology	-	-	3	20	8
Steriles	19	8	19	23	15
Patented	-	-	3	6	4
Matured	19	8	19	37	19


*includes 4 filed in 2011

NUMBER OF ANDA APPROVALS (LMV- \$0.7 Bn)



Oncology					1
Steriles		1	13	3	4
Patented					1
Matured		1	13	3	17

CUMULATIVE LMV OF ANDA APPROVALS (US\$ BN)



Oncology					
Steriles		0.0	0.3	0.3	0.7
Patented					0.1
Matured		0.0	0.3	0.3	0.6

Number of filings & Approvals in other Established and Emerging markets

	Filings		Approvals	
	Steriles	Oncology	Steriles	Oncology
Europe	22	18	6	1
Australia	17	8	14	-
South Africa	66	5	25	-
Canada	20	-	19	-
New Zealand	1	2	1	-
Africa	142	1	109	1
Latin America	157	-	123	-
ROW	145	49	87	8
Total	570	83	384	10


1 Note: LMV (Local Market value): 2009 sales in US\$ of equivalent products already being sold in the market, whether patented or generic.
3 LMV is not an indicator of Strides' expected sales;

Recent successes in line with new strategy

Bulk of ANDA approvals yet to be commercialized



Commercialisation pipeline




Major Commercialized products

	Vancomycin	Rifampicin	Azithromycin
Addressable market value (LMV)	\$157 mn	\$8 mn	\$28 mn
Partner	Pfizer	Pfizer	Sagent
No. of Players	7	3	6
Filing year	2006	2006	2007
Approval date	Dec 2008	May 2008	Mar 2009
Commercialized date	Feb 2009	June 2008	April 2009
Market share*	11%	59%	18%

Licensing income (US\$m)

Received \$100mn licensing fee in year 2010



LMV (Local Market value): 2009 sales in US of equivalent products already being sold in the market, whether patented or generic.

LMV is not an indicator of Strides' expected sales; LMV source: IMS Health as on 10 Aug 2010

Note: Includes licensing income from both Pharma and Steriles businesses

USD/INR exchange rate used: 45.67

*MAT IMS Sept'10

Global partnerships an endorsement of Strides' strong capabilities

PFIZER

Jan 2010: Collaboration on Generic Products

- Pfizer to commercialize 40 off patent products (to be licensed / supplied by Strides) – primarily injectable cancer medicines to healthcare providers and patients in the United States

May 2010: Partnership strengthened

- Oncology products extended to EU, Australia, Korea, Japan and Canada
- Additional niche sterile injectable products included for the US market
- Collaboration now extends to a total of 45 products addressing countries across the globe

Dec 2010: Sold 22 ANDAs (16 approved)

- Entered into long term agreement for manufacture and supply of these products

Why Strides?

- ✓ Strides is a powerhouse in the steriles injectable area
- ✓ Pfizer looked at more than 100 companies before settling on the deal with Strides
- ✓ This collaboration is new and exciting, and we are encouraged about the potential of this relationship
- ✓ We view this as a beginning of a partnership and look at Strides as a strong anchor point

Comments by: David Simmons – President & General Manager, Established Products Business Unit – Pfizer

GSK

➤ Deal is transformational for GSK

- (Source: GSK Press Release)

➤ GSK shares profits and pays licensing fees

➤ Arrangement for 95 countries worldwide

➤ First 10 products from Strides

Why Strides?

"This collaboration gives us access to a renewable, high quality and competitively priced source of branded pharmaceuticals in high demand therapeutic areas, Aspen, through its own pipeline and that of its joint venture with Strides has a product portfolio of over 450 molecules and 1200 products which complements our own product portfolio and will enable us to deliver more medicines of value to more patients in these countries"

Comments by: Andrew Witty – CEO of GSK

Source: Pfizer Press Release – Jan 10 and GSK Press Release – July 2008

Other Global Partners

➤ Sandoz

➤ Teva

➤ Novartis

➤ Aspen

➤ Apotex

➤ Martindale

➤ Sagent

➤ ICN

➤ Actavis


Biosimilars-Unfolding Opportunities



<p>Market Overview</p>	<ul style="list-style-type: none"> ➤ Biologics* market expected to grow at a CAGR of 8%-10% during 2010 to 2025, against 4%-6% for total pharmaceutical market ➤ Biologics worth \$ 59 Billion to lose patent protection by 2015 ➤ Biologics market expected to touch \$227 billion by 2015 against \$126 billion in 2009 ➤ Biosimilars# market expected to touch \$13 billion by 2015 ➤ 6 Biosimilars already approved and commercialized in EU
<p>Agila Foray into Biosim Domain</p>	<ul style="list-style-type: none"> ➤ Acquired 70% controlling stake in Inbiopro-a biotechnology focused company
<p>Competitive Advantage</p>	<ul style="list-style-type: none"> ➤ Immediate access to a pipeline of 8 products, estimated to have global sales of US\$ 28 billion, with commercialization expected to begin in 2013 ➤ The products include 5 monoclonal antibodies which have use in cancer treatment further strengthening Strides' oncology products basket ➤ Facilities access to high expression mammalian and microbial platform-based capabilities ➤ High yielding cell lines in-licensed and improved upon ➤ Definite advantage in the biologics industry, which is characterized by specialized expertise in recombinant DNA technology and manufacturing process development with stringent and well defined regulatory guidelines ,resulting in long gestation periods for product development

Significant FDA Approved capacities

Capex towards 261m additional sterile units capacity completed and approved



Capacity augmentation plan

- ✓ Executed agreement with Malaysian Bio-Xcell for establishment of customized facility to manufacture Biopharmaceuticals and sterile Injectables in the Bio-XCell ecosystem in Johor, Malaysia.
- ✓ Facility will be built by Bio-XCell to the design requirements of Strides and will be leased out to Strides on a long-term basis with lease rentals applicable from the date of commercialization .

USFDA Inspection Status


Plant	Year	Approval Status
Sterile Product Division -I	2007, 2009	Approved
Penicillin	2008	Approved
Cephalosporin	2009	Approved
Sterile Product Division -II	2011	Approved
Oncology	2011	Approved
Penems	Inspection by H2'2011	

- Well positioned in the industry where regulatory challenges are high

Benefits of operating leverage as new capacity supports roll out of new approvals



Manufacturing site particulars		Existing facilities			New facilities			Poland
		Steriles	Penicillins	Cephalo- sporins	Steriles	Penicillins & Penems	Oncology	
Location		Bangalore India	Bangalore India	Bangalore India	Bangalore India	Campos Brazil	Bangalore India	Warsaw Poland
USFDA approval status	Plant	✓	✓	✓	✓	Awaited	✓	Primary focus on European Mkt
	Products	✓	Awaited	Awaited	✓	Awaited	Awaited	EU approved Plant
Total capacity (mn units)		64	33	44	140	66	25	56
Filings (US)	Nos	53	8	5	21	2	30	N.A.
Approvals (US)	Nos	38	Nil	Nil	1+38	Nil	1	N.A.


 All FDA approved products can be moved from one FDA approved plant to another within 30-120 days



Pharma & Brand Business



Pharma business – A Snapshot



Globally competitive	<ul style="list-style-type: none"> ✿ Amongst the leading manufacturers of soft gelatin capsules in the world ✿ Supplies oral products to regulated markets
Product development capability	<ul style="list-style-type: none"> ✿ Develops and manufactures different orals presentation forms and therapeutic categories <ul style="list-style-type: none"> – Softgel caps, tablets & capsules and semi solids – Strength in Immunosuppressants (2 Approved ANDA commercialized) ✿ 38 ANDA (21 PEPFAR) filings till date of which 22 (17 PEPFAR) have already been approved
Stable revenue stream	<ul style="list-style-type: none"> ✿ Orals plants – can support growth with limited Capex requirements going forward ✿ Large number of product filings completed ✿ Long term customer contracts to provide stable revenue stream ✿ Intellectual property led manufacturing partnership in USA, UK, Australia, New Zealand and South Africa
Manufacturing overview	<ul style="list-style-type: none"> ✿ One of largest softgel capacities in the world with five dedicated lines in Orals Drug facility in Bangalore, India ✿ Facility approved by major regulatory authorities such as USFDA, MHRA, MCC, TGA and ANVISA ✿ EU approved semi solids facility in Milan, Italy ✿ Commercialised first FDA approval for a Softgel product (Ergocalciferol Capsules 1.25mg) through Perrigo/Paddock under a profit share partnership

Branded generics business -snapshot

Regional Sales exceeding US\$165 million




	Australasia	Africa	India
Description	<ul style="list-style-type: none"> Operating as Ascent Pharmahealth, a leading pharmaceutical, generic and consumer health company 	<ul style="list-style-type: none"> Leading player manufacturing and marketing volume driven generics and margins driven branded products 	<ul style="list-style-type: none"> Emerging as a niche player in branded pharmaceutical products
Manufacturing	<ul style="list-style-type: none"> Dedicated facility in Jurong, Singapore 	<ul style="list-style-type: none"> 3 dedicated facilities: 1 in Lagos, Nigeria and 2 in India 	<ul style="list-style-type: none"> Orals plant in Bangalore also used for manufacturing branded generics
Footprint	<ul style="list-style-type: none"> Australia (5th largest) & Singapore (Largest) with growing operations in 5 other Emerging South-East Asian markets 	<ul style="list-style-type: none"> West Africa, French Africa & other parts of Africa 	<ul style="list-style-type: none"> Grandix has presence in 5 states in South India
Products	<ul style="list-style-type: none"> Ethically promoted generic pharmaceuticals, OTC and skincare (prescription and consumer) products with some well established consumer brands such as Avene (Skincare), Hairy Lemon (OTC) and Estelle (Prescription medicine) and Dermorganics (Organic Skincare) 	<ul style="list-style-type: none"> Branded generics, Commodity generics and OTC products marketed through own sales team in partnership with local distributors French Africa business is front ended comprising ethically promoted and OTC products 	<ul style="list-style-type: none"> Grandix covers therapeutic areas of diabetes, cardiovascular diseases, neurology and female healthcare
Sales	<ul style="list-style-type: none"> US\$128mn 	<ul style="list-style-type: none"> US\$30mn 	<ul style="list-style-type: none"> US\$10mn
Ownership	<ul style="list-style-type: none"> 94% Stake Recently Privatized 	<ul style="list-style-type: none"> 100% stake 	<ul style="list-style-type: none"> 100% stake



Financials


Organization Structure




Key Financials




Revenue from operations⁽¹⁾ (US\$mn)




Operational EBITDA⁽¹⁾ (US\$mn)



Profit after tax (US\$mn)



Margins trend




Note: (1) Excludes profit on sale of investment (c.US\$ 55mn in 2008) and exchange fluctuation gain on sale of investment (c.US\$ 10mn in 2008)
All income statement items, USD/INR exchange rate used:45.59


Key Financials (cont'd)




Gross block (US\$mn)




Declining Debt/Equity



Earnings per share (US\$)



Return on capital employed




**H1'11 EPS and ROCE are annualised figures
 For balance sheet items, closing USD/INR exchange rate used: 44.69
 For income statement items, average USD/INR exchange rate used: 45.59*


Debt Management



Debt evolution (Net of Cash) since Dec 2009 (US\$mn)



Debt composition (US\$mn)



Leverage ratios	
Net Debt to equity	1.3x
Net Debt to EBITDA (Annualized)	4.2x
Interest coverage ratio	2.7x
Cash & cash equivalent (US\$ m)	75.9


Major Cash Outflows - 2010	\$Mn
FCCB Redemption	48
Acquisition of Brazil Business	68
Acquisition of 50% Oncology Stake	87
Capital Expenditure	42
Inbiopro	7
Preference Shares Redemption	7
Total	259

Note: All balance sheet items, USD/INR exchange rate used:44.69


Market View



Strong Institutional support for the stock



Shareholding Pattern



*as on 27th May '11

- Stock price appreciated by 87% during the year 2010
- Successfully placed \$100Mn QIP in 2010
- Increase in Outstanding Shares from 40Mn in Dec'09 to 58Mn in Dec'10

An abstract graphic consisting of numerous thin, curved lines that flow from the left side of the page towards the right. The lines are color-coded, with a gradient from light blue at the top to yellow at the bottom. They curve downwards and then upwards, creating a sense of movement and depth. The lines are densely packed in some areas and more sparse in others, creating a textured, organic feel.

Key Takeaways

Emerging compelling business



1. Focus on high margin specialties business
2. Large number of ANDA filings – 157 (119 in Steriles and 38 in Pharma)
3. Significant ramp-up in Capacities - recently approved by FDA
4. Bulk of the approved Sterile products in process of commercialization
5. Foray into new domains of Ophthalmics, Biosims and Peptides to open up new avenues
6. Significant investment in organic and inorganic expansion completed
7. Global partnerships with the likes of Pfizer, GSK and Aspen etc.
8. Pool of around 350 scientists to drive R&D growth



Thank You

Strides Arcolab Limited
Strides House, Bilekahalli, Bannerghatta Road
Bangalore 560076, India
Tel: +91 80 67840738 / 67840290
Fax: +91 80 67840200
Web: www.stridesarco.com

